Presented by Dr. James Underberg, MS, MD, FACPM, FACP, FASH, FASH, FASPC      

Educational Objectives:

Upon completion of this activity, participants should be better able to:

  • Summarize the diagnostic evaluation and current clinical guidelines for the treatment of hyperlipidemia
  • Identify the mechanisms of action and safety-efficacy data of currently available and emerging investigational lipid-lowering therapies
  • Employ available clinical evidence to recognize patients who may benefit from emerging PCSK9-targeting therapies
  • Evaluate the role of multidisciplinary collaboration and patient education to optimize outcomes in patients with hyperlipidemia.

Dr. Underberg is a Clinical Lipidologist. He is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is also the Director of the Bellevue Hospital Lipid Clinic. Dr. Underberg holds joint appointments in the divisions of General Internal Medicine and Endocrinology at NYU.

Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and Past President of the National Lipid Association.  He is a Fellow of the National Lipid Association , President of the American Board of Clinical Lipidology & Vice President of the Foundation of the National Lipid Association. He serves on the editorial board of the Journal of Clinical Lipidology and is a board member of the Foundation of the National Lipid Association and the American Board of Clinical Lipidology. 

Dr. Underberg’s Clinical Interests focus on the clinical management of patients with lipids and lipoprotein disorders and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of Clinical Lipidology. He sees patients both at Bellevue Hospital and in a University-based Private practice setting. 

Sponsored by PeerView Institute for Medical Education.

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

 

FMM21 - Management of Hyperlipidemia in the Family Medicine Setting: Diagnosis, Management and the Role of Emerging Lipid-lowering Therapies
Course - Management of Hyperlipidemia in the Family Medicine Setting: Diagnosis, Management and the Role of Emerging Lipid-lowering Therapies
Evaluation

Course Details

© Copyright 2022 | Terms | Privacy | MC LMS, Inc. | Designed by Boldare